Navigation Links
NOVAVAX Announces Release Date of 2010 Year-End Financial Results and Investor Conference Call

ROCKVILLE, Md., March 23, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2010 year-end financial results in a press release to be issued after 8:00 a.m. local time Monday, March 28, 2011 and will then hold an investor conference call at 10:00 a.m. The call will be hosted by Novavax's  President and Chief Executive Officer, Dr. Rahul Singhvi and other members of senior management. The dial-in number for the conference call is 1 (877)-212-6076 (U.S. or Canada) or 1 (707)-287-9331 (International).

A live audio webcast of the conference call will be available at under Investors/Events. A replay of the conference call will be available on Novavax's website approximately one-hour after the event for 90 days and a replay will also be available by telephone beginning March 28, 2011. To access the replay, dial 1-(800)-642-1687 and enter pass code 54520344.

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like particles (VLPs) technology and single-use bioprocessing system enables rapid vaccine development and production where and when it's needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website:  

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NOVAVAX to Present at BIT Life Sciences 3rd World Congress of Vaccine
2. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
3. NOVAVAX to Present at Citi 2011 Global Health Care Conference
4. NOVAVAX to Present at 13th Annual BIO CEO & Investor Conference
5. NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
6. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
7. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
8. NOVAVAX Elects Richard H. Douglas to its Board of Directors
9. Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer
10. Novavax Announces Manufacturing Management Appointments
11. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
Breaking Biology News(10 mins):